dc.contributor.author
Maurer, Max M.
dc.contributor.author
Ibach, Marius
dc.contributor.author
Plewe, Julius
dc.contributor.author
Winter, Axel
dc.contributor.author
Ritschl, Paul
dc.contributor.author
Globke, Brigitta
dc.contributor.author
Öllinger, Robert
dc.contributor.author
Lurje, Georg
dc.contributor.author
Schöning, Wenzel
dc.contributor.author
Pratschke, Johann
dc.contributor.author
Eurich, Dennis
dc.date.accessioned
2022-09-05T09:42:20Z
dc.date.available
2022-09-05T09:42:20Z
dc.identifier.uri
https://refubium.fu-berlin.de/handle/fub188/36164
dc.identifier.uri
http://dx.doi.org/10.17169/refubium-35880
dc.description.abstract
Non-adherence to immunosuppressant therapy reduces long-term graft and patient survival after solid organ transplantation. The objective of this 24-month prospective study was to determine adherence, efficacy and safety after conversion of stable liver transplant (LT) recipients from a standard twice-daily immediate release Tacrolimus (IR-Tac) to a novel once-daily life cycle pharma Tacrolimus (LCP-Tac) formulation. We converted a total of 161 LT patients at baseline, collecting Tacrolimus trough levels, laboratories, physical examination data and the BAASIS(C) questionnaire for self-reported adherence to immunosuppression at regular intervals. With 134 participants completing the study period (17% dropouts), the overall adherence to the BAASIS(C) increased by 57% until month 24 compared to baseline (51% vs. 80%). Patients who required only a morning dose of their concomitant medications reported the largest improvement in adherence after conversion. The intra-patient variability (IPV) of consecutive Tacrolimus trough levels after conversion did not change significantly compared to pre-conversion levels. Despite reducing the daily dose by 30% at baseline as recommended by the manufacturer, Tac-trough levels remained stable, reflected by an increase in the concentration-dose (C/D) ratio. No episodes of graft rejection or loss occurred. Our data suggest that the use of LCP-Tac in liver transplant patients is safe and can increase adherence to immunosuppression compared to conventional IR-Tac.
en
dc.rights.uri
https://creativecommons.org/licenses/by/4.0/
dc.subject
immunosuppressant adherence
en
dc.subject
immunosuppressant efficacy
en
dc.subject
liver transplantation
en
dc.subject.ddc
600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit::610 Medizin und Gesundheit
dc.title
Reducing the Pill Burden: Immunosuppressant Adherence and Safety after Conversion from a Twice-Daily (IR-Tac) to a Novel Once-Daily (LCP-Tac) Tacrolimus Formulation in 161 Liver Transplant Patients
dc.type
Wissenschaftlicher Artikel
dcterms.bibliographicCitation.articlenumber
272
dcterms.bibliographicCitation.doi
10.3390/biomedicines10020272
dcterms.bibliographicCitation.journaltitle
Biomedicines
dcterms.bibliographicCitation.number
2
dcterms.bibliographicCitation.originalpublishername
MDPI AG
dcterms.bibliographicCitation.volume
10
refubium.affiliation
Charité - Universitätsmedizin Berlin
refubium.resourceType.isindependentpub
no
dcterms.accessRights.openaire
open access
dcterms.bibliographicCitation.pmid
35203481
dcterms.isPartOf.eissn
2227-9059